VSA012 not checked

Bisirna Therapeutics (Suzhou) Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
3 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Paroxysmal Nocturnal Hemoglobinuria, PNH, Paroxysmal Nocturnal Hemoglobinuria (PNH)
Main trialPhase 3
“A study of the efficacy and safety of VSA012 Injection compared to eculizumab for 24 weeks in patients with PNH.”In the company’s words, NCT07816237 on ClinicalTrials.gov

Other drugs for Paroxysmal Nocturnal Hemoglobinuria, PNH

All 23 drugs for Paroxysmal Nocturnal Hemoglobinuria, PNH

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 30 Sep 2027 A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
Phase 1Active, not recruiting Aug 2026 A Phase I Clinical Study of VSA012 in Healthy Volunteers
Phase 1Active, not recruiting 28 Feb 2027 Phase Ib Clinical Study to Evaluate the Safety and Tolerability of VSA012 Injection in Paroxysmal Nocturnal Hemoglobinuria
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow VSA012

Following is part of Solo: you see every change to VSA012 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in